Home » Stocks » PRQR

ProQR Therapeutics N.V. (PRQR)

Stock Price: $4.02 USD -0.08 (-1.95%)
Updated November 24, 4:00 PM EST - Market closed
After-hours: $4.09 +0.07 (1.74%) Nov 24, 5:12 PM

Stock Price Chart

Key Info

Market Cap 201.57M
Revenue (ttm) 2.17M
Net Income (ttm) -63.76M
Shares Out 50.14M
EPS (ttm) -1.31
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 24
Last Price $4.02
Previous Close $4.10
Change ($) -0.08
Change (%) -1.95%
Day's Open 4.14
Day's Range 4.02 - 4.26
Day's Volume 238,387
52-Week Range 3.60 - 10.98

More Stats

Market Cap 201.57M
Enterprise Value 91.02M
Earnings Date (est) Mar 3, 2021
Ex-Dividend Date n/a
Shares Outstanding 50.14M
Float 43.42M
EPS (basic) n/a
EPS (diluted) -1.31
FCF / Share -1.24
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 704,218
Short Ratio 3.24
Short % of Float 1.62%
Beta 0.77
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 92.81
PB Ratio 2.42
Revenue 2.17M
Operating Income -64.54M
Net Income -63.76M
Free Cash Flow -50.75M
Net Cash 110.55M
Net Cash / Share 2.20
Gross Margin 100.00%
Operating Margin -2,971.81%
Profit Margin -2,935.60%
FCF Margin -2,336.83%
ROA -36.94%
ROE -81.51%
ROIC -812.80%
Key stats in USD, based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (5)

Buy 5
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(449.63% upside)
Current: $4.02
Target: 22.09
*Average 12-month USD price target from 5 stock analysts.

Financial Performance

Financial numbers in millions EUR.

Financial Overview

Revenue Growth-66.45%285.35%-18.22%-43.49%933.55%169.83%-
Gross Profit1.935.761.501.833.240.310.12
Operating Income-57.45-36.29-40.50-39.57-27.00-16.46-3.24
Net Income-56.75-37.09-43.68-39.10-20.83-12.13-3.25
Shares Outstanding41.0434.0525.3723.3523.3411.085.52
Earnings Per Share-1.38-1.08-1.72-1.67-0.89-1.09-0.59
Operating Cash Flow-44.59-28.62-35.10-34.22-24.23-14.46-2.33
Capital Expenditures-0.58-0.31-0.12-2.54-1.30-1.11-0.14
Free Cash Flow-45.17-28.93-35.22-36.76-25.53-15.57-2.47
Cash & Equivalents11210648.1059.2094.871134.13
Total Debt13.569.397.245.704.842.863.54
Net Cash / Debt98.3996.1940.8653.5090.031100.59
Book Value94.3392.9239.3653.1489.80109-0.09
Numbers in millions EUR, except per-share numbers.

Company Profile

Company Details

Full Name ProQR Therapeutics N.V.
Country Netherlands
Employees 154
CEO Daniel Anton de Boer

Stock Information

Ticker Symbol PRQR
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: PRQR
IPO Date September 18, 2014


ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It is primarily developing sepofarsen that is in phase II/III illuminate trial for treating leber's congenital amaurosis 10 disease; QR-421a, which is in phase 1/2 stellar trial for usher syndrome type 2 and non-syndromic retinitis pigmentosa; QR-1123 that is in phase 1/2 aurora trial for the treatment of autosomal dominant retinitis pigmentosa; and QR-504a, which is in first clinical trial for the treatment of fuchs endothelial corneal dystrophy. It has a license agreement with General Hospital Corporation, Radboud University Medical Center, Inserm Transfert SA, and Leiden University Medical Center. ProQR Therapeutics N.V. was founded in 2012 and is headquartered in Leiden, the Netherlands.